State run refineries stand to gain as govt raised the FDI limit to 49 per cent from 26 per cent.
Suzlon Energy is relocating its management team to Amsterdam to span their global business.
To be modelled on the Carnegie Mellon University.
According to sources, the company will invest $350-400 million in the proposed plant. This will be the first foray by an Indian company for manufacturing cement in West Asia which was so far viewed as an export market.
The Indian Institutes of Technology (IITs) have a 2008 budget wishlist. They want the government to grant them more funds to support their infrastructure expansions and research initiatives.
Foreign B-schools are finding great potential in India's growing economy and are therefore coming up with executive education programmes and centres here.
The US-based Chartered Financial Analyst Institute has decided to approach the All India Council for Technical Education to seek approval for its India operations.
Multinational drug manufacturers such as Pfizer and DSM are increasingly getting into contract manufacturing alliances with emerging bulk drug makers in the country, bypassing established players such as Ranbaxy and Dr Reddy's.
Oil India chief reveals plans of the upcoming IPO and future investment strategies.
Cipla tops pharma rankings with 5.42% market share, ahead of Ranbaxy and GSK.
The largest such refiner -- Indian Oil Corporation -- has earmarked over Rs 13,500 crore (Rs 135 billion) to meet these specifications (essentially lower sulphur and aromatic hydrocarbons) in petrol and diesel at its seven refineries.
Oil and Natural Gas Corporation (ONGC), the country's leading oil and gas exploration and production company, is entering the alternative energy segment with a Rs 1,200 crore-plus (Rs 12 billion) investment to generate 200 mw of wind power for captive use, within two years.
With 40 million diabetic patients and an equal number of people estimated to be diabetic prone, India is emerging as a major market for blood glucose monitoring solutions.
Consequently, the thousands of first- and second-level students (comparable to first year and second year) will now have to go abroad to pursue the CFA course if they still wish to do so. This would mean an additional expense of thousands of dollars besides heartburn and anxiety.
In another setback to Big Pharma, US drug major Eli Lilly's blockbuster erectile dysfunction drug Cialis (generic name:Tadalafil) has failed to qualify for a product patent in India after the basic constituent of the medicine was found to be a known substance, developed and patented by Indian scientists 32 years ago.
After Harvard Business School and Tuck School of Business, India's developing corporate scenario has now attracted France-based ESCP-EAP European School of Management to hold executive education programmes for corporates in India.
Anil Kumble would be raking in around Rs 60-75 lakh a year for endorsing Manipal Education. Viswanathan Anand would be getting anywhere between Rs 75 lakh to Rs 1 crore. Universities are choosing sports icons as brand endorsers as they not only want to portray themselves as excellent in academics, but extra-curricular performances too.
Interestingly, the European Patent Office is yet to grant a patent for Maraviroc, citing insufficient data, sources said. These were the main reasons cited by the Indian Patent Office for rejecting the patent for the cancer drug Gleevec, which snowballed into a global patent battle between the Swiss drug major Novartis and the Indian government.
Suzlon Energy, one of the top five wind energy manufacturers in the world, plans to raise $500 million (Rs 2,000 crore) through the Qualified Institutional Placement (QIP) route to fund its expansion plans.
Industry bigwigs and corporate heavyweights have been scurrying to get the best students for themselves. Naturally, salaries are headed north.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances